Kronos Bio (NASDAQ:KRON) 주식

Kronos Bio

Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.

Commodities

Exclusives

Interview

AMCR

BERY

BMWYY

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

GOOG

GOOGL

KRON

MEIP

NISTF

PARA

SAVE

SBUX

SHEL

TSX:SGO

ULCC

VWAGY

새로이 등장한 블록 스타벅스(NASDAQ:SBUX)가 중국 사업의 일부 지분을 매각하려고 한다. 최근 1분기 중국 내 동일 매장 매출이 14% 감소하면서, 시애틀에 본사를 둔 이 커피 소매업체는 치열한 경제적 및 경쟁적 압박에 적응하기 위한 파트너십을 모색하고 있다.

딜 디스패치: 스타벅스 중국 사업 매각 고려, 노스볼트 파산, 다윈 파이낸셜이 광업에 대해 논의

AAUKF

APTV

ATSG

FFIV

PARIS:SGO

ROIC

SLGWF

SLNG

TRIP

새로 등장한 블록 에볼런트 헬스(NYSE:EVH)가 매물로 나온 것으로 알려졌다. 버지니아 주 알링턴에 본사를 둔 이 소프트웨어 회사는 인수 문의를 받은 후 경매 프로세스를 시작했다. 잠재적인 구혼자 중에는 TPG(NASDAQ:TPG), 클레이톤, 듀블리에 &amp; 라이스(Clayton, Dubilier &amp; Rice), KKR &amp; 컴퍼니(NYSE:KKR)가 있다. 로이터는 건강 보험사 엘레반스 헬스(NYSE:ELV)가 한 사모 펀드 파트너와 협력하여 거래를 추진할 수 있다고 보고했다.

딜 디스패치: 쉘, 유니레버 외에도 매각 뉴스; 어니언이 알렉스 존스의 인포워스 인수 등

Kronos Bio Inc

Krones AG

KRONOS ADVANCED TECHS INC by Kronos Advanced Technologies, Inc.

Kronos Advanced Technologies Inc

Kronos Worldwide Inc

Piper Sandler analyst Mark Lear maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Overweight and raises the price target from $34 to $37.

News

Price Target

Analyst Ratings

CTRA

Piper Sandler Maintains Overweight on Coterra Energy, Raises Price Target to $37

Guidance

Macy's CEO Says Consumers Remain Under Pressure Navigating From An Inflation Rate And Yet Wanting To Indulge At Times; Says 'I Don't Think The Consumer Is Going To Feel A Sense Of Relief In The Short Term'

<ul>
<li>Proactive steps reinforce bioAffinity Technologies' laser focus on accelerating CyPath&#xAE; Lung sales growth in strategic national markets</li>
<li>Decreases labor and overhead costs, including 38% workforce reduction in non-CyPath&#xAE; Lung personnel at Company's subsidiary laboratory</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbioaffinitytech.com%2F&amp;esheet=54220116&amp;newsitemid=20250306388376&amp;lan=en-US&amp;anchor=bioAffinity+Technologies&amp;index=1&amp;md5=35df396edda935fc0a25014d8944a15f">bioAffinity Technologies</a>, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>, BIAFW)), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced targeted strategic actions to improve financial performance and accelerate the commercial growth of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cypathlung.com&amp;esheet=54220116&amp;newsitemid=20250306388376&amp;lan=en-US&amp;anchor=CyPath%26%23174%3B+Lung&amp;index=2&amp;md5=a255ade8a66b4dc2743693184fe3bafd">CyPath&#xAE; Lung</a>, the Company's noninvasive test for early-stage lung cancer. The Company expects these measures to deliver approximately $4 million in annual cost savings at its subsidiary Precision Pathology Laboratory Services (PPLS), while increasing resources to expand CyPath&#xAE; Lung sales in high-potential national markets.

BIAF

bioAffinity Technologies Announces Targeted Strategic Actions To Improve Financial Performance And Accelerate The Commercial Growth Of CyPath Lung; Expects These Measures To Deliver ~$4M In Annual Cost Savings

Macy's CFO Says For Q1 Expect These Pressures Along With Inflation And Tariffs To Continue

WIIM

ONVO

Organovo shares are trading higher after the company announced issuance of additional shares.

Piper Sandler analyst Mark Lear maintains Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) with a Overweight and lowers the price target from $71 to $66.

CIVI

Piper Sandler Maintains Overweight on Civitas Resources, Lowers Price Target to $66

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/06063601/CSPC-PharmaW.png" alt="" class="wp-image-7261" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/06063601/CSPC-PharmaW.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/06063601/CSPC-PharmaW-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/06063601/CSPC-PharmaW-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The generic drugs giant has warned of a 26% slide in annual profits after China's national healthcare system imposed big price cuts on qualifying medicines

<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>CSPC Pharma was already on track for a tough earnings season after its nine-month profits fell 15.9%</li>
<li>Another blow was the sudden departure of the firm's head of innovative drug research, Liu Yongjun, a well-known industry figure</li>
</ul>
Is the gloss coming off the crown for one of the kings of China's drugs industry?
A profit warning late last month from drugs giant&nbsp;CSPC Pharmaceutical Group Ltd.&nbsp;(1093.HK) does beg the question. After enjoying growing sales of cancer drugs and antibiotics, the company is now facing a steep drop in its&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0225/2025022500951.pdf">full-year profits</a>, hit by price controls for its signature products under China's national healthcare system.
After the market close on February 25, CSPC Pharma said it expected its net profit for 2024 to have fallen about 26% from the 5.87 billion yuan ($807 million) it earned in 2023. The drop was blamed on a 7% decline in takings from the finished drug business, the main pillar of the company's earnings.
Finished drugs brought in 13.55 billion yuan, 83% of total revenue, in the first half of 2024. CSPC Pharma, one of four so-called kings of the Chinese generic drugs business, also sells raw materials for antibiotics, vitamin C products and other supplements.
In the statement, CSPC Pharma blamed its earnings slide on China's centralized drug procurement process, which had slashed the prices of key products. A drug used to elevate white blood cells during chemotherapy had its price cut by 58% under the bulk deal. Another CSPC Pharma drug for lymphoma and breast or ovarian cancer was discounted by 23% in the same procurement round, the company said.
Sales of these two star products, Jinyouli and Duomeisu, have been falling since the bulk purchasing policy was gradually rolled out across Chinese regions over the past year, the company said. The revenue from oncology therapeutics therefore plunged around 28% in 2024 compared with the prior year.
Any products knocked out of the bulk bidding will not suffer big price cuts, but losing access to this centrally coordinated market would also take its toll on earnings. CSPC Pharma pointed out that sales of Xuanning, a drug for hypertension and angina, had fallen sharply in hospitals that had adopted the new system, after the product failed to be selected in a procurement round in 2023. As a result, revenue from the cardiovascular therapeutic area fell approximately 15% in 2024 from the previous year.
Pitching competitive bids for national health contracts is a key revenue factor for a company like CSPC Pharma, which produces a wide range of generic drugs. Fifteen of its products were selected in the latest national procurement round. Eight of the winning CSPC Pharma bids were the cheapest in the mix, according to details that emerged from a meeting last December of the national purchasing agency. As well as the price, the body also took the firm's high-tech manufacturing capability and in-house production of active pharmaceutical ingredients into account, judging that CSPC Pharma could deliver quality products even at the cheaper rate.
In fact, CSPC Pharma was already heading for a weak full-year result. Its operating revenue rose just 1.3% to 6.28 billion yuan in the first half of 2024, for a net profit of 3.2 billion yuan. &nbsp;Given that profits for the first nine months fell 15.9%, the slide must have accelerated in the fourth quarter to justify the latest full-year projection.
<h4 class="wp-block-heading">Developing new drugs</h4>
In recent years, many veteran suppliers of generic drugs have been shifting their focus to emerging treatments, partly to offset central procurement's bargaining power. One of the other "four kings",&nbsp;Hengrui Pharmaceuticals&nbsp;(600276.SH), is taking the lead in moving up the value chain to produce innovative drugs. Hengrui's profits shrank for two straight years before it managed to offset the procurement squeeze in 2023. Since then, Hengrui has returned to earnings growth on the back of its novel drug business.
CSPC Pharma has also been investing heavily in innovative drug research and development since 2018, although most of the resulting compounds are still at the clinical trial stage. The candidate drugs include mRNA vaccines and targeted therapies using antibody drug conjugates (ADCs) as well as monoclonal or bispecific antibodies.
So far only three of the drugs have been approved for sale, and the new pipelines will not make up for lost revenue from discounted generics in the health program. In its half-year results for 2024, the company said it had around 60 key drugs under development, of which seven have been submitted for marketing approval and 19 are still entering the clinical stage.
The challenges have been compounded by executive changes. Last September, CSPC Pharma welcomed a new head of global R&amp;D who had previously worked for Innovent and had built up standing in the industry. Liu Yongjun was given a brief to speed up the development program, but he left suddenly after just three months in the job, raising concerns about the pace of progress towards a portfolio of advanced drugs.
On the positive side, the company has also entered into a series of licensing deals. Most Chinese companies keep hold of the domestic market when they sell marketing rights to new or candidate drugs, but CSPC is taking a different approach. Its latest agreements transfer global rights including Greater China to its partners, suggesting the company may intend to specialize in the preliminary phase of R&amp;D.
Global development and sales rights for a potential lipid-lowering therapy as well as experimental drugs for a variety of cardiovascular diseases were sold to&nbsp;AstraZeneca&nbsp;(AZN.US) in October last year. The deal gives CSPC Pharma up to $2 billion, including a down payment of $100 million (729 million yuan). Two months later the drug giant licensed out its global interests in a drug for cancers with a gene mutation known as MAT2A to&nbsp;BeiGene&nbsp;(6160.HK, BGNE.US). CSPC Pharma gets an upfront fee of up to $150 million, development payments of up to $135 million and further fees of up to $1.55 billion if it hits sales milestones, as well as royalties.
The income from those deals should burnish CSPC Pharma's results, but at the cost of lucrative benefits down the road if the drugs eventually go on sale. The firm currently trades at a price-to-earnings (P/E) ratio of just 10 times, far lower than the 54 times for Hengrui Pharmaceuticals. The company's stock has slipped since the profit warning, but the price remains virtually flat for the year to date.
With underwhelming earnings, CSPC Pharma will need to show swift progress on innovative drugs if it wants to inspire more confidence among investors.

Asia

Health Care

CSPC Pharma's Earnings Hit By China's Drug Price Control Measures

Macy's CFO Says There Were Some Unexpected Factors In The Early Part Of The Quarter With The Fires And Cold Weather That Impacted Results

Piper Sandler analyst Mark Lear maintains Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) with a Overweight and lowers the price target from $193 to $184.

CHRD

Piper Sandler Maintains Overweight on Chord Energy, Lowers Price Target to $184

Arrow will enable enhanced security postures and streamlined security operations for its channel partner base across the U.S. and Canada with the CrowdStrike Falcon platform
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fen-us%2F&amp;esheet=54220103&amp;newsitemid=20250306620213&amp;lan=en-US&amp;anchor=CrowdStrike&amp;index=1&amp;md5=af04d664c76fd75479c7fe48bf4a1048">CrowdStrike</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) today announced a distribution agreement with Arrow Electronics, bringing the industry-leading <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fplatform%2F&amp;esheet=54220103&amp;newsitemid=20250306620213&amp;lan=en-US&amp;anchor=CrowdStrike+Falcon%26%23174%3B+cybersecurity+platform&amp;index=2&amp;md5=9c4a270c2719d317b0b36ef590211735">CrowdStrike Falcon&#xAE; cybersecurity platform</a> to Arrow channel partners and customers across the U.S. and Canada. This collaboration expands CrowdStrike's robust channel ecosystem, enabling Arrow's channel partner base of leading resellers, CSPs, MSPs and MSSPs to drive system consolidation and help stop breaches with the world's most advanced AI-native cybersecurity.
Arrow is committed to bringing the best cybersecurity solutions to its channel partner base serving both enterprise and mid-market customers across North America. With deep expertise in powering SIEM, cloud and cybersecurity transformation services, Arrow will leverage <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fplatform%2Fnext-gen-siem%2F&amp;esheet=54220103&amp;newsitemid=20250306620213&amp;lan=en-US&amp;anchor=Falcon%26%23174%3B+Next-Gen+SIEM&amp;index=3&amp;md5=0a1e87f3043abe98d923ef313af5aa16">Falcon&#xAE; Next-Gen SIEM</a>, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fplatform%2Fcloud-security%2F&amp;esheet=54220103&amp;newsitemid=20250306620213&amp;lan=en-US&amp;anchor=Falcon%26%23174%3B+Cloud+Security&amp;index=4&amp;md5=cf5c8d2eac5caf4ea9b25e20cecf8b37">Falcon&#xAE; Cloud Security</a> and the broader Falcon platform, providing its channel partners with the ability to modernize security operations and address customer challenges around consolidating vendor costs and closing protection gaps between disjointed point products.
Through <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.arrow.com%2Fglobalecs%2Fna%2Fplatforms%2Farrowsphere%2F&amp;esheet=54220103&amp;newsitemid=20250306620213&amp;lan=en-US&amp;anchor=ArrowSphere&amp;index=5&amp;md5=0a70a443a8243ccb0fa7a62faae5fb26">ArrowSphere</a> marketplace, channel partners can seamlessly procure and deploy the Falcon platform, simplifying security management and accelerating adoption with flexible billing, streamlined licensing, and easy integration with existing IT infrastructure.

CRWD

CrowdStrike Signs Distribution Agreement With Arrow Electronics, Enabling Enhanced Security Postures And Streamlined Security Operations For Its Channel Partner Base Across The U.S. And Canada With The CrowdStrike Falcon Platform

LPSN

LivePerson shares are trading lower after the company reported a Q4 EPS miss and issued Q1 revenue guidance below estimates.

Benchmark analyst David Williams reiterates Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) with a Buy and maintains $14 price target.

Reiteration

RGTI

Benchmark Reiterates Buy on Rigetti Computing, Maintains $14 Price Target

Orion Office REIT shares are trading lower. The company reported Q4 financial results.

Earnings

RAPT

RAPT Therapeutics Q4 EPS $(1.14) Misses $(0.36) Estimate

Piper Sandler analyst Mark Lear maintains Black Stone Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSM#NYSE">BSM</a>) with a Neutral and raises the price target from $14 to $16.

Piper Sandler Maintains Neutral on Black Stone Minerals, Raises Price Target to $16

- LuxOS firmware upgrade completed, improving fleet efficiency
- Bitcoin HODL 165.8 BTC as of February 28, 2025 valued at $14.6 million or $2.85 per share1
TAMPA, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- LM Funding America, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/LMFA#NASDAQ">LMFA</a>) ("LM Funding" or the "Company"), a Bitcoin mining and technology-based specialty finance company, today announced its preliminary, unaudited Bitcoin mining and operational update for the month ended February 28, 2025.
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td>Metric</td>
<td>Dec 2024</td>
<td>Jan 2025</td>
<td>Feb 2025</td>
</tr>
<tr>
<td>- Bitcoin2</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>- Mined, net</td>
<td>7.0</td>
<td>8.0</td>
<td>8.1</td>
</tr>
<tr>
<td>- Sold</td>
<td>(4.0)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>- Purchased</td>
<td>5.0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>- Service Fee</td>
<td>-</td>
<td>-</td>
<td>(0.5)</td>
</tr>
<tr>
<td>- Bitcoin HODL</td>
<td>150.2</td>
<td>158.2</td>
<td>165.8</td>
</tr>
<tr>
<td>- Machines2</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>- Operational</td>
<td>3,681</td>
<td>5,121</td>
<td>5,121</td>
</tr>
<tr>
<td>- Storage</td>
<td>2,159</td>
<td>719</td>
<td>719</td>
</tr>
<tr>
<td>- Total Machines</td>
<td>5,840</td>
<td>5,840</td>
<td>5,840</td>
</tr>
<tr>
<td>- Hashrate (EH/s2)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>- Oklahoma</td>
<td>0.29</td>
<td>0.43</td>
<td>0.43</td>
</tr>
<tr>
<td>- Hosted</td>
<td>0.13</td>
<td>0.13</td>
<td>0.13</td>
</tr>
<tr>
<td>- Energized</td>
<td>0.42</td>
<td>0.56</td>
<td>0.56</td>
</tr>
<tr>
<td>- Storage</td>
<td>0.21</td>
<td>0.07</td>
<td>0.07</td>
</tr>
<tr>
<td>- Total</td>
<td>0.63</td>
<td>0.63</td>
<td>0.63</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

LMFA

LM Funding America Announces February 2025 Production And Operational Update; Mined 8.1 BTC; Holds 165.8 BTC As Of Feb. 28, 2025

BioAffinity Technologies shares are trading higher after the company announced targeted actions to cut $4 million in costs and drive CyPath® Lung sales growth.

Events

BRNS

Barinthus Biotherapeutics To Present At Investor Summit Virtual On Mar. 11

General

BLIN

Bridgeline Completes SOC 2 Type II Audit

Toro Company Reiterates FY25 Outlook: Sees Sales Growth Of 0%-1% And Adjusted Diluted EPS Of $4.25-$4.40 Vs. $4.32 Estimate

Press Releases

Kronos Bio Announces Participation in Medical and Investor Conferences in September

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

Comments

Kronos Bio

뉴스

파트너 / 기고자

벤징가 글로벌